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Available online 13 May 2016Objectives: To investigate one-year outcomes after implantation of a bioresorbable vascular scaffold (BVS) in
patients presenting with acute coronary syndrome (ACS) compared to stable angina patients.
Background: Robust data on the outcome of BVS in the setting of ACS is still scarce.
Methods: Two investigator initiated, single-center, single-arm BVS registries have been pooled for the purpose of
this study, namely the BVS Expand and BVS STEMI registries.
Results: From September 2012–October 2014, 351 patients with a total of 428 lesions were enrolled. 255 (72.6%)
were ACS patients and 99 (27.4%) presented with stable angina/silent ischemia. Mean number of scaffold/patient
was 1.55 ± 0.91 in ACS group versus 1.91 ± 1.11 in non-ACS group (P = 0.11). Pre- and post-dilatation were
performed less frequent in ACS patients, 75.7% and 41.3% versus 89.0% and 62.0% respectively (P = 0.05 and P =
0.001). Interestingly, post-procedural acute lumen gain and percentage diameter stenosis were superior in ACS pa-
tients, 1.62 ± 0.65 mm (versus 1.22 ± 0.49 mm, P b 0.001) and 15.51 ± 8.47% (versus 18.46 ± 9.54%, P = 0.04).
Major adverse cardiac events (MACE) rate at 12 months was 5.5% in the ACS group (versus 5.3% in stable group,
P=0.90). One-year deﬁnite scaffold thrombosis ratewas comparable: 2.0% for ACSpopulation versus 2.1% for stable
population (P = 0.94), however, early scaffold thromboses occurred only in ACS patients.
Conclusions: One-year clinical outcomes in ACS patients treated with BVS were similar to non-ACS patients. Acute
angiographic outcomes were better in ACS than in non-ACS, yet the early thrombotic events require attention
and further research.
© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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Drug-eluting stents (DES) are the ﬁrst choice devices in percutane-
ous coronary interventions (PCI). Despite recent advantages, shortcom-
ings related to the use of DES still are present such as delayed arterial
healing, late stent thrombosis (ST), neo-atherosclerosis and hypersensi-
tivity reactions to the polymer [1,2].MS, bare metal stent; BVS,
affold; CABG, coronary artery
inical events committee; DES,
ular ultrasound; LM, left main;
farction; MLD, minimal lumen
I, non-ST elevationmyocardial
taneous coronary intervention;
y; RVD, reference vessel diame-
ial infarction; TLF, target lesion
essel revascularization; UA, un-
.
5, Erasmus Medical Center, s-
Geuns).
land Ltd. This is an open access articlTo overcome these limitations, coronary devicesmade of fully biore-
sorbable material were developed to provide mechanical support and
drug-delivery within the ﬁrst year, followed by complete resorption.
The ﬁrst bioresorbable vascular scaffold (BVS) was commercially intro-
duced in September 2012 as the Absorb BVS (Abbott Vascular, Santa
Clara, CA). The BVS provides transient vessel support and gradually
elutes the anti-proliferative drug everolimus. After degradation of the
polymer (after approximately two to three years) no foreign material
remains and need for late reintervention triggered by foreign material
should thus be reduced [3].
First-in-man trials have proven the safety of the BVS up to ﬁve years
[4,5] with a fully completed bioresorption process, a late luminal
enlargement due to plaque reduction and a persistent restoration of
vasomotion [6–8]. The 1-year results of the larger ABSORB II, ABSORB
Japan, ABSORB China and ABSORB III randomized controlled trials
comparing BVS with DES (Xience V), conﬁrmed the safety in relatively
simple coronary lesionswith similar clinical event rates for both devices
[9–12].
In all these early studies, ACS patients were largely excluded while
BVS would comprise a more attractive choice in this setting as ACS pa-
tients are in general youngerwith a longer life expectancy, less previouse under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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would conﬂict with a therapy aiming at maximal recovery and restora-
tion of normal anatomy of both the coronary artery and myocardium.
Furthermore, lesions primarily consisting of soft plaque would be
conceptually easy to expand thus facilitating BVS implantation in ACS
population. On the other hand, ACS patients are in a much higher pro-
thrombotic state which might accelerate thrombus formation on the
larger struts of the BVS impactingmuchmore on shear stress compared
to the thinner struts of current metallic DES.
Few registries focused on the performance of the BVS in patients
presenting with ACS, mainly ST-elevation myocardial infarction
(STEMI). BVS STEMI First examined the procedural and short-term
clinical outcomes of 49 STEMI patients, revealing excellent results:
procedural success was 97.9% and only 1 patient suffered an event
(non-target vessel MI) [13]. Kočka et al. reported similar results in
the Prague-19 study [14]. Extending the initial Prague-19 study, the BVS
Examination is currently the largest registry on BVS in STEMI with en-
couraging MACE rates (Device oriented clinical endpoint: 4.1% at one
year for both the BVS and the DES), although with a not negligible deﬁ-
nite/probable scaffold thrombosis rate (2.4% at one year for the BVS) [15].
The recently published TROFI II randomized trial investigated arteri-
al healing in 90 STEMI patients treated with a BVS compared to those
treated with an everolimus-eluting stent (EES). Based on OCT, arterial
healing at 6 months after BVS implantation was non-inferior to that
after EES implantation [16].
In general, the previous studies on BVS in ACS are limited in size and
procedural details and there is a need for more data on the efﬁcacy of
BVS in the setting of PCI for ACS. The aim of this study was to compare
the angiographic and clinical outcomes of BVS in ACS patients with stable
patients.Fig. 1. Flowch2. Material and methods
2.1. Population
Two investigator-initiated, prospective, single-center, single-arm
studies performed in an experienced, tertiary PCI center have been
pooled for the purpose of this investigation. Patients presenting with
NSTEMI, stable or unstable angina (UA), or silent ischemia caused by a
de novo stenotic lesion in a native previously untreated coronary artery
with intention to treatwith a BVSwere included in BVS Expand registry.
Angiographic inclusion criteriawere lesionswith a Dmax (proximal and
distal maximal lumen diameter) within the upper limit of 3.8 mm and
the lower limit of 2.0 mm by online quantitative coronary angiography
(QCA). Complex lesions such as bifurcation, calciﬁed (as assessed by
angiography), long and thrombotic lesions were not excluded. Exclu-
sion criteria were patients with a history of coronary bypass grafting
(CABG), presentationwith cardiogenic shock, bifurcation lesions requir-
ing kissing balloon post-dilatation, ST-elevation myocardial infarction
(STEMI) patients, allergy or contra-indications to antiplatelet therapy,
fertile female patients not taking adequate contraceptives or currently
breastfeeding and patients with expected survival of less than one
year. As per hospital policy patients with a previously implanted metal
DES in the intended target vessel were also excluded. Also, although
old age was not an exclusion criterion, BVS were in general reserved
for younger patients, and left to operator's interpretation of biological
age.
Patients presenting with STEMI, were approached to participate in
the BVS STEMI Registry, which started twomonths after the BVS Expand
registry. The study design has been described elsewhere [13]. The most
important inclusion criteria were presentation with STEMI and com-
plaints b12 h. The remaining inclusion criteria were similar to the
BVS-EXPAND registry.art study.
Table 1
Patient characteristics.
ACS patients Non-ACS patients P value
Number of patients (%) 255 (72.6) 96 (27.4)
Mean age in years (±SD) 57.9 ± 10.7 63.4 ± 8.9 b0.001
Gender (%)
Male 191/255 (74.9) 73/96 (76.0) 0.84
Female 64/255 (25.1) 23/96 (24.0) 0.84
Smoking (%) 149/255 (58.4) 44/96 (45.8) 0.03
Hypertension (%) 130/253 (51.0) 55/95 (57.3) 0.29
Dyslipidemia (%) 92/251 (36.1) 49/95 (51.0) 0.01
All diabetes mellitus (%) 33/255 (12.9) 18/98 (18.8) 0.16
Insulin dependent 7/255 (2.7) 3/96 (3.1) 1.00
Family history of CAD (%) 104/252 (40.8) 39/94 (41.5) 0.94
History of MI (%) 25/255 (9.8) 21/96 (21.9) 0.003
History of PCI (%) 12/255 (4.7) 12/96 (12.5) 0.01
Cardiogenic shock (%) 5/255 (2.0) 0/96 (0.0) 0.33
Renal insufﬁciency (%) 8/255 (3.1) 8/88 (8.3) 0.046
Presentation (%) b0.001
Stable angina 0/255 (0.0) 95/96 (99.0)
Unstable angina 40/255 (15.6) 0/96 (0.0)
STEMI 120/255 (46.9) 0/96 (0.0)
NSTEMI 95/255 (37.3) 0/96 (0.0)
Silent ischemia 0/255 (0.0) 1/96 (1.0)
Single vessel disease (%) 183/255 (71.5) 52/96 (54.2) 0.02
P2Y12 inhibition use b0.001
Clopidogrel 60/255 (23.5) 86/96 (89.6)
Prasugrel 164/255 (64.3) 9/96 (9.4)
Ticagrelor 30/255(11.8) 1/96 (1.0)
Values are expressed as percentages or mean ± standard deviation when appropriate.
P values are based on Chi square test or Fishers' exact test for categorical variables and
Student's t test for continuous variables. ACS: acute coronary syndrome, CAD: coronary
artery disease,MI:myocardial infarction, NSTEMI: non-ST elevationmyocardial infarction,
PCI: percutaneous coronary intervention, STEMI: ST elevation myocardial infarction.
Table 2
Lesion characteristics.
ACS patients
N = 255,
L = 300
Non-ACS
patients
N = 96, L = 128
P value
Number of lesions per patient 1.18 ± 0.49 1.33 ± 0.56
Left anterior descending artery (%) 48.0 54.4 0.23
Left circumﬂex artery (%) 24.3 20.0 0.38
Right coronary artery (%) 27.7 25.6 0.61
Bifurcation (%) 20.3 30.7 0.009
Calciﬁcation (moderate or severe) (%) 31.8 50.4 b0.001
(Chronic) total occlusion(%) 26.2 8.7 b0.001
CTO (%) 1.7 7.0 0.007
ACC/AHA lesion classiﬁcation (%)
A 14.1 15.0 0.75
B1 53.4 41.7 0.02
B2 24.2 22.0 0.66
C 7.2 19.7 b0.001
TIMI (%)
Pre-procedure b0.001
TIMI 0 25.2 9.4
TIMI I 4.6 0.8
TIMI II 16.1 6.3
TIMI III 52.1 81.9
Post-procedure 0.61
TIMI 0 0.0 0.0
TIMI I 0.3 0.0
TIMI II 4.6 3.1
TIMI III 93.4 95.3
Values are expressed as percentages or mean ± standard deviation when appropriate.
P values are based on Chi square test or Fishers' exact test for categorical variables and
Student's t test for continuous variables. ACS: acute coronary syndrome (ST-elevation
myocardial infarction, non-ST myocardial infarction and unstable angina), non-ACS: non
acute coronary syndrome (stable angina and silent ischemia).
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This is an observational study, performed based on international
regulations, including thedeclaration of Helsinki. Approval of the ethical
board of the Erasmus MC was obtained. All patients undergoing clinical
follow-up provided written informed consent to be contacted regularly
during the follow-up period of the study.
2.3. Procedure
PCI was performed according to current clinical practice standards.
The radial or femoral approach using 6 or 7 French catheters were the
principal route of vascular access. Pre-dilatation was recommended
with a balloon shorter than the planned study device length. Advanced
lesion preparation was left to the operator's discretion. Post-dilatation
was recommendedwith anon-compliant balloonwithout overexpanding
the scaffold beyond its limits of expansion (by N0.5mm larger than nom-
inal diameter). Intravascular imaging with the use of Intravascular
Ultrasound (IVUS) or Optical Coherence Tomography (OCT) was
used for pre-procedural sizing and optimization of scaffold deploy-
ment on the discretion of the operator. All patients were treated with
unfractionated heparin (at a dose of 70–100 UI/kg). Patients with stable
anginawere preloadedwith 300mg of aspirin and 600mg of clopidogrel.
Patients presenting with ACS were preloaded with 300mg of aspirin and
60 mg of prasugrel or 180 mg of ticagrelor.
2.4. Angiographic analysis
The angiographic analysis was performed by three independent
investigators (YI, JF and YO). Coronary angiograms were analyzed
with the CAAS 5.10 QCA software (Pie Medical BV, Maastricht, the
Netherlands). The QCAmeasurements provided reference vessel diam-
eter (RVD), percentage diameter stenosis (%DS), minimal lumen diam-
eter (MLD), and maximal lumen diameter (Dmax). Acute gain was
deﬁned as post-procedural MLD minus pre-procedural MLD (in an oc-
cluded vessel MLD value was zero by default).
2.5. Follow-up
Survival status of all patients was obtained frommunicipal civil reg-
istries. Follow-up information speciﬁc for hospitalization and cardiovas-
cular events was obtained through questionnaires. If needed, medical
records or discharge letters from other hospitals were collected. Events
were adjudicated by an independent clinical events committee (CEC).
2.6. Deﬁnitions
The primary endpointwasMACE, deﬁned as the composite endpoint
of cardiac death, myocardial infarction (MI) and target lesion revascu-
larization (TLR). Deaths were considered cardiac unless a non-cardiac
cause was deﬁnitely identiﬁed. TLR was described as any repeated re-
vascularization of the target lesion. Target vessel revascularization
(TVR) was deﬁned as any repeat percutaneous intervention or surgical
bypass of any segment of the target vessel. Non-target vessel revascular-
izationwas described as any revascularization in a vessel other than the
vessel(s) of the target lesion(s). Target lesion failure (TLF) was deﬁned
as a composite endpoint of cardiac death, target vesselMI and TLR. Scaf-
fold thrombosis (ST) and MI were classiﬁed according to the Academic
Research Consortium (ARC) [17]. Clinical device success was deﬁned
as successful delivery and deployment of the ﬁrst study scaffold/stent
at the intended target lesion and successful withdrawal of the delivery
system with attainment of ﬁnal in-scaffold/stent residual stenosis of
b30% as evaluated by QCA. Clinical procedure success was described
as device success without major peri-procedural complications or in-
hospital MACE (maximum of 7 days).The intention-to-treat (ITT) group includes all the patients re-
gardless of whether or not the scaffold was successfully implanted.
The per-treatment (PT) group consists of all patients in whom the
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PT group.
As a measure of scaffold expansion, the expansion index was calcu-
lated as post-procedural MLD divided by nominal device diameter. A
cut-off value of b0.70 below was used to deﬁne underexpansion.
2.7. Statistical analysis
Categorical variables are reported as counts and percentages, contin-
uous variables as mean ± standard deviation. The Student's t test and
the chi square test (or Fishers' exact test) were used for comparison of
means and percentages. The cumulative incidence of adverse events
was estimated according to the Kaplan–Meier method. Patients lost
to follow-up were considered at risk until the date of last contact, at
which point they were censored. Kaplan–Meier estimates were com-
pared bymeans of the log-rank test. For the endpointMACE, a landmark
survival analysis was performed with the landmark time point of
30 days. All statistical tests were two-sided and the P value of b0.05
was considered statistically signiﬁcant. Statistical analyses were per-
formed using SPSS, version 21 (IL, US).
A univariate logistic regression analysis was performed to look for
predictors of TLF and probable/deﬁnite ST.Table 3
Procedural and angiographical characteristics.
ACS N = 255
Procedural characteristics
Aspiration (%) 34.4
Rotablation (%) 1.0
Scoring balloon (%) 1.3
Invasive imaging at baseline (%)
OCT 25.2
IVUS 9.9
Pre-dilatation (%) 75.7
Pre-dilatation balloon: artery ratio 1.01 ± 0.21
Maximum pre-dilatation balloon diameter (mm) 2.57 ± 0.42
Maximum pre-dilatation inﬂation pressure (atm) 13.96 ± 3.02
Buddy wire (%) 9.8
Daughter catheter (%) 3.6
Total number of scaffolds implanted 394
Mean number of scaffolds/patient 1.55 ± 0.91
Mean number of lesions/patient 1.18 ± 0.49
Mean scaffold diameter (mm) 3.14 ± 0.37
Mean scaffold length (mm) 20.35 ± 5.67
Overlap (%) 20.7
Post-dilatation (%) 41.3
Post-dilation balloon: mean scaffold diameter ratio 1.23 ± 0.21
Maximum post-dilatation balloon diameter (mm) 3.38 ± 0.42
Maximum post-dilatation inﬂation pressure (atm) 15.40 ± 3.00
Clinical device success (%) 98.0
Clinical procedural success (%) 95.4
Angiographical characteristics
Mean lesion length (mm) 22.41 ± 12.24
Pre-procedure, overall
RVD (mm ± SD) 2.65 ± 0.54
MLD (mm ± SD) 0.69 ± 0.51
DS (%) 64.82 ± 42.0
Pre-procedure, non-total occlusion
RVD (mm ± SD) 2.60 ± 0.48
MLD (mm ± SD) 0.89 ± 0.39
In-scaffold DS (%) 65.45 ± 20.91
Pre-procedure, total occlusion
(L = 80 for ACS and L = 11 for non-ACS)
RVD (mm ± SD) 2.81 ± 0.69
Post-procedure, overall
RVD (mm ± SD) 2.79 ± 0.48
MLD (mm ± SD) 2.35 ± 0.42
In-scaffold DS (%) 15.57 ± 8.47
Acute gain (mm ± SD) 1.62 ± 0.65
Values are expressed as percentages ormean±standarddeviationwhenappropriate. P values a
for continuous variables. ACS: acute coronary syndrome (ST-elevation myocardial infarction, no
(stable angina and silent ischemia), %DS: percentage diameter stenosis, IVUS: intravascular ima
vessel diameter.3. Results
From September 2012 up to October 2014, 452 patients were
intended to be treated with one or more BVS. Thirteen patients
were excluded based on protocol related exclusion criteria of the
BVS Expand registry and the BVS STEMI registry and 79 patients de-
clined to participate in one of the two follow-up registries. Thus 360
patients (intention-to-treat group) remained for the purpose of this
study. There were 9 cases of device failure in which a metallic stent
was implanted and the per-treatment group consisted of 351 patients. A
ﬂowchart of the study is given in Fig. 1.
3.1. Baseline characteristics
Baseline characteristics are presented in Table 1. Presentation with
ACSwas present in 72.6% of the patients and 27.4%were stable patients.
Mean age was signiﬁcantly different between the two groups: 57.9 ±
10.7 years for ACS patients and 63.4 ± 8.9 years for non-ACS patients
(P b 0.001). Dyslipidemia, history of MI, history of PCI and renal insufﬁ-
ciency were factors that occurred signiﬁcantly more frequent in stable
patients. ACS patients had more single vessel disease (71.5% versus
54.2%, P = 0.02)., L = 300 Non-ACS N = 96, L = 128 P value
0.0 b0.001
5.6 0.02
3.9 0.14
36.2 0.10
24.8 b0.001
89.0 0.05
1.05 ± 0.25 0.11
2.60 ± 0.34 0.49
14.01 ± 3.41 0.91
10.2 0.74
4.0 0.80
183
1.91 ± 1.11 0.11
1.33 ± 0.56 0.015
3.02 ± 0.38 0.003
20.75 ± 5.99
31.5 0.04
62.2 0.001
1.31 ± 0.23 0.11
3.19 ± 0.42 0.003
16.10 ± 3.31 0.17
97.7 0.82
96.9 0.49
24.58 ± 14.58 0.35
2.57 ± 0.45 0.22
1.04 ± 0.40 b0.001
47.94 ± 43.48 b0.001
2.58 ± 0.44 0.72
1.06 ± 0.37 0.002
58.62 ± 13.84 0.002
1.78 ± 1.34 b0.001
2.77 ± 0.43 0.66
2.26 ± 0.38 0.05
18.46 ± 9.54 0.04
1.22 ± 0.49 b0.001
re based on Chi square test or Fishers' exact test for categorical variables and Student's t test
n-ST myocardial infarction and unstable angina), non-ACS: non acute coronary syndrome
ging, OCT: optical coherence tomography, MLD: minimal lumen diameter, RVD: reference
Table 4
Clinical outcomes at one year.
ACS
(N = 255)
Non-ACS
(N = 96)
P value
All-cause death (%) 0.0 (0) 3.2 (3) 0.05
Cardiac 0.0 (0) 3.2 (3) 0.05
Non-Cardiac 0.0 (0) 0.0 (3) –
MACE (%) 5.5 (14) 5.3 (5) 0.90
Myocardial infarction (%) 5.1 (13) 2.1 (2) 0.22
Target lesion revascularization (%) 3.1 (8) 3.2 (3) 0.99
Target vessel revascularization (%) 3.5 (9) 3.2 (3) 0.86
Non-target vessel revascularization (%) 3.2 (8) 5.5 (5) 0.35
Overall scaffold thrombosisa (%) 2.4 (6) 4.2 (4) 0.37
Deﬁnite scaffold thrombosis (%) 2.0 (5) 2.1 (2) 0.94
Acute 1.2 (3) 0.0 (0) 0.29
Subacute 0.4 (1) 0.0 (0) 0.54
Late 0.4 (1) 2.1 (2) 0.12
Deﬁnite/probable scaffold thrombosis (%) 2.4 (6) 2.1 (2) 0.88
Acute 1.2 (3) 0.0 (0) 0.29
Subacute 0.4 (1) 0.0 (0) 0.54
Late 0.8 (2) 2.1 (2) 0.30
Event rates are summarized as %. P values are based on log rank test for comparing Kaplan
Meier. MACE: major adverse cardiac events (composite endpoint consisting of cardiac
death, myocardial infarction and target lesion revascularization).
a Includes deﬁnite, probable and possible ST.
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left anterior descending coronary artery (LAD) was most commonly
treated (48.0% in ACS group and 54.4% in non-ACS group, P = 0.23).
Lesions in stable patients weremore complex, with a higher percentage
of AHA/ACC typeB2/C lesions. Pre-procedural TIMIﬂowwas signiﬁcant-
ly different (P b 0.001). Themean lesion length was comparable in both
groups (24.58 ± 14.58 mm for non-ACS versus 22.41 ± 12.24 mm for
ACS, P = 0.35) (Table 3). Pre-procedural QCA analysis revealed signiﬁ-
cant differences between the groups in MLD: 0.69 ± 0.51 mm for ACS
patients versus 1.04 ± 0.40 in stable patients (P b 0.001). After exclud-
ing the thrombotic total occlusions, this statistical difference remained
(0.89 ± 0.39 mm for ACS versus 1.06 ± 0.37 mm for non-ACS, P =
0.002). Pre-procedural %DSwas 65.45±20.91% in the ACS group versus
58.62 ± 13.84% in non-ACS group (P b 0.001). Post-procedural QCA
measurements revealed a superior acute performance in the ACS popu-
lation: remaining %DS was signiﬁcant lower (15.57 ± 8.47% versus
18.46± 9.54%, P= 0.04). Final MLDwas larger (2.35± 0.42mmversus
2.26 ± 0.38 mm, P = 0.05) and also acute lumen gain was higher
(1.62 ± 0.65 mm versus 1.22 ± 0.49 mm, P b 0.001).
3.2. Procedural details
Procedural and angiographic details are summarized in Table 3.
In ACS patients, pre-dilatation was performed in 75.7% of the lesions,
compared to 89.0% in stable patients (P = 0.05). Pre-dilatation balloonFig. 2. Kaplan–Meier curve for MACE.to artery ratio was comparable (1.01 ± 0.21 versus 1.05 ± 0.25, P =
0.11). Post-dilatation was signiﬁcantly less frequently performed in
the ACS group (41.3% versus 62.2%, P = 0.001). Advanced lesion prepa-
ration was less often performed in ACS patients than in stable patients
(rotational atherectomy: 1.0% versus 5.6%, P = 0.02; scoring balloon
1.3% versus 3.9%, P = 0.14). A total of 582 BVS were implanted: 399 in
the ACS group (with a mean of 1.55 ± 0.91 scaffolds per patient) and
183 in stable patients (with a mean of 1.91 ± 1.11 per patient in stable
patients).
In the ACS population 6 cases of device failure occurred, all due to
delivery failure. Main causes of these delivery failures were calciﬁcation
and angulation (see Table 6 for details). Eight in-hospitalMACEwere re-
ported. Whereas in the stable population 3 device failures (placement
metal DES due to dissection after BVS implantation and delivery failures
due to severe calciﬁcation and tortuosity) and no in-hospital MACE
were documented in stable patients. Clinical device and procedural suc-
cesswere 98.0% and 95.4% for theACS population and 97.7 and96.9% re-
spectively for stable patients.
3.3. Clinical outcomes
Data on survival status was available in 100% with a median follow-
up period of 731 days (interquartile range [IQR]: 550–769 days). A total
of 340 (96.9%) patients had a follow-up duration of at least 365 (±2)
days.
Cumulative clinical events rates are summarized in Table 4. Clinical
outcomes appeared to be comparable with no signiﬁcant difference be-
tweenpatients presentingwith ACS as compared to stable patients. Rate
of death was 0.0% in the ACS group versus 3.1% in the non-ACS group
(P = 0.06). Three patients died within the ﬁrst year. One patient, with
extensive cardiovascular disease died at day 166, 4 days after he went
through a deﬁnite ST and MI, most probably due to a brief interruption
of his antithromboticmedication during an elective surgery. The second
patient died a few days after his prostatewas surgically removed. In this
case, dual antiplatelet inhibition therapy (DAPT) was also shortly
interrupted causing aMI (probable ST). The last patient died of a sudden
cardiac death 66 days after baseline PCI (possible ST).
MACE rate in the ACS population was comparable to the non-ACS
population (5.5% versus 5.3%, P=0.90, Fig. 2).MACEwasmainly driven
byMI and TLR. TLR ratewas comparable in both groups. Rate of TVRwas
in 3.2% in ACS patients versus 3.5% in stable patients (P = 0.86). Non-
TVR rate was 3.2% and 5.5% in respectively ACS and non-ACS patients
(P = 0.350). Rate of deﬁnite ST was similar in both groups: 2.0% in the
ACS group versus 2.1% in stable patients (P = 0.94). Of note, early ST
only occurred in the ACS group, late thrombosis was more prevalent
in stable patients (Table 4 and Fig. 3B).
A landmark survival analysis of MACE, deﬁnite/probable ST, MI and
TLR indicated a trend for higher event rates of the ACS population in
the short-term (b30 days). Conversely, mid-term event rates were
higher in stable patients, although log rank test failed to prove signiﬁ-
cance (Fig. 3A–D).
In an univariate analysis of TLF the following characteristics tended
to be related by at least a twofold increase in odds ratio (OR): renal in-
sufﬁciency, bifurcation, male gender and age above 65 years (Table 5).
The use of intravascular imaging at baseline might be protective for
TLF (OR 0.49, P = 0.22).
4. Discussion
The present study reports on the comparative procedural and the
one-year clinical outcomes of ACS patients versus non-ACS patients
treated with an Absorb bioresorbable scaffold. The main ﬁndings of
this study are summarized as follows: 1) angiographic outcomes were
better in ACS patients despite the fact that less aggressive lesion prepa-
ration and less frequent post-dilatationwere performed; 2) overall one-
year ST rate in ACS patients was similar to the non-ACS patients.
Fig. 3. A–D Landmark survival analysis for MACE, probable/deﬁnite ST, MI and TLR.
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while late ST seemed more frequent in stable patients; 3) despite the
higher rate of early complications in the ACS group, landmark analyses
after one month demonstrated that event rates were lower in this
group than the stable patient group; and 4) clinical outcomes at one
year were comparable among ACS and stable patients.
Differences between ACS patients and stable patients exist at multi-
ple levels. On a patient level, patients presenting with ACS often are
younger and thus have a longer life expectancy. Cardiovascular disease
in this group is less extensive when compared to stable patients.
Additionally, a different plaque composition is present, featured by a
lipid-rich necrotic core with a thin ﬁbrous cap. All these factors make
ACS patients very attractive for bioresorbable technologies where full
expansion is important and acute recoil a concern.Moreover, in ACS pa-
tients DAPT pretreatment is usually short (especially in STEMI patients)
and frequently not yet resulting in active platelet function inhibition,
while the thrombus burden is greater with high platelet activation
and a systemic inﬂammatory response. These factors might amplify
the risk of acute thromboses and cause a higher risk of MACE. For
these reasons studies like ours are important to investigate theTable 5
Univariate analysis of TLF.
Odds ratio ACS vs. non ACS
(95% conﬁdence interval)
P value
Renal insufﬁciency 3.28 (0.68–15.83) 0.14
Bifurcation 2.68 (0.98–7.36) 0.06
Male gender 2.38 (0.53–10.69) 0.26
Age above 65 years 2.10 (0.77–5.75) 0.15
History of MI 1.57 (0.43–5.73) 0.50
Small vessel (b2.5 mm) 1.54 (0.56–4.20) 0.40
Post-procedural TIMI 0/1 1.45 (0.53–3.99) 0.47
Underexpansion 1.30 (0.46–3.66) 0.62
Calciﬁcation 1.26 (0.46–3.46) 0.66
Long lesion (N32 mm) 1.20 (0.33–4.36) 0.78
Smoking 1.07 (0.74–1.54) 0.72
Diabetes mellitus 0.83 (0.18–3.78) 0.81
Presentation with ACS 0.82 (0.28–2.43) 0.72
Intravascular imaging at baseline 0.49 (0.15–1.54) 0.22
ACS: acute coronary syndrome, MI: myocardial infarction, TLF: target lesion failure (cardiac
death, target vessel MI, ischemia driven TLR).suitability of BVS in ACS patients. To the best of our knowledge, no
data is available comparing the performance of BVS in ACS with stable
patients compared to stable patients.
The BVS Expand registry and the BVS STEMI registry are two single-
center, single-arm registries describing procedural clinical outcomes of
patients treated with BVS. At variance of previous studies investigating
the Absorb bioresorbable scaffold, all events were adjudicated by an
independent clinical event committee (CEC). Also, all angiograms
were analyzed using QCA. Lastly, combining the results of the two reg-
istries, both handling less restrictive inclusion criteria, we were able to
create a study population reﬂecting a real-world populationwith a con-
siderable amount of ACS patients.
The superior acute angiographic outcome in ACS patients compared
to stable patients is an important observation. In previous studies it was
demonstrated that the acute performance of the Absorb scaffold is
somewhat inferior to metallic stents for stable angina patients. For
example, in-device acute lumen gain in the ABSORB II trial was
1.15 ± 0.38 mm in BVS group versus 1.46 ± 0.38 mm in the EES
group (P b 0.001). In the ABSORB III trial reported lumen gain was
1.45 ± 0.45 mm versus 1.59 ± 0.44 mm (P b 0.001). Finally, in the
ABSORB Japan and ABSORB China trials acute lumen gain numbers
were as follows: 1.46 ± 0.40 mm versus 1.65 ± 0.40 mm (P b 0.0001)
and 1.51 ± 0.03 versus 1.59 ± 0.03 (P = 0.04) respectively. Remark-
ably, in STEMI patients no difference in acute gain was observed be-
tween BVS and DES (2.16 ± 0.52 mm versus 2.21 ± 0.56 mm, P =
0.57). This ﬁnding also suggests that the somewhat inferior angiograph-
ic results only imply for stable angina patients while the current semi-
compliant balloon and wide strut BVS design are sufﬁcient for the gen-
eral softer plaque composition of ACS patients. In the current study,
post-dilatation was signiﬁcantly less frequently performed in ACS pa-
tients, however angiographic outcomes were better. Post-procedural
MLD, RVD, %DS and in-scaffold acute lumen gain were all superior com-
pared to post-procedural QCA measurements in stable patients. These
promising angiographic results in ACS patients support the use BVS in
this setting as they are predictive for clinical events.
Overall, one-year ST rate in ACS patients was similar to the non-ACS
patients. The observed rate of early ST in the ACS populationmight raise
some concerns. Previous studies have stated that presentationwith ACS
is an independent risk factor for the development of (metal) stent
Table 6
Details device failures in ACS population.
Age
(yr.)
Gender Presentation Culprit Location AHA/ACC Calc. Bif. Ang. Tort. Additional device Treatment
1 71 M NSTEMI RCA RCA B2 Severe No No No PT Graphix Super
Support
3.0 × 28, 3.0 × 28 Xience
2 37 M UAP RCA LCx B1 No No Yes No None 2.5 × 12 Xience
3 60 M UAP LCx LCx B2 Moderate No Yes No None 2.5 × 18, 2.25 × 12 Xience
4 47 M STEMI LAD LAD B2 No Yes No Yes STO1 Heartrail 3.5 × 23 Xience
5 71 F UAP RCA RCA B2 Severe No No No Rotablator 4 Promus stents
6 59 M UAP LCx LCx B2 Severe Yes Yes No STO1 Heartrail 3.5 × 8 Xience
Ang = angulation, Bif = bifurcation, Calc = calciﬁcation, NSTEMI = non-ST elevation myocardial infarction, STEMI = ST elevation myocardial infarction, Tort = tortuositas,
UAP = unstable angina pectoris.
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mented that stenting of lesions with appeared plaque rupture are
prone to delayed healing, characterized by higher percentages of uncov-
ered, malapposed and protruding stent struts with a subsequent risk of
stent thrombosis [21–24]. Furthermore, underexpansion appeared to be
an important predictor [25–27]. This is also the case for ST in BVS pa-
tients [28,29]. In ACS patients, high thrombus burden, increased platelet
activation and vasospasm are mechanisms that trouble optimal sizing
resulting in higher rates of malapposition. In the acute setting, lesion
preparation using pre-dilatation and intravascular imaging are less fre-
quently performed than in stable patients. Although the acute scaffold
expansion is on average better in the ACS population than in the stable
population, it is very important to properly size the vessel and to opti-
mize the ﬁnal scaffold expansion in order to avoid early ST.
The landmark analysis beyond one month up to 12 months
showed favorable results with regard to ST and TLR for the ACS pa-
tients (0.8% and 1.2% respectively). The somewhat higher event rates
in the non-ACS group are a representation of a more complex non-
study real world patient population. Therefore, the one-year MACE
(composite of cardiac death, MI and TLR) rates of 5.5% (ACS) and
5.3% (non-ACS) are acceptable and comparable to trials using BVS in
relatively simple lesions: 5.0% in the ABSORB II trial and 3.8% in the
ABSORB China trial [9,12]. A comparable endpoint, target lesion failure
(TLF: composite endpoint consisting of cardiac death, target vessel MI
and ischemia driven TLR), in the ABSORB III and ABSORB Japan trials
were 7.8% and 4.2% respectively [10,11]. In these studies, STEMI pa-
tients were excluded. Compared to studies investigating clinical out-
comes of metal DES in STEMI patients, event rates in our report are
higher than for EES but for lower compared to ﬁrst-generation DES
[30,31].
Recently, few concerns were raised concerning a potentially in-
creased incidence of ST after implantation of a BVS [27,32–34]. Also, in
our registry rate of deﬁnite ST (2.0% for ACS patients and 2.1% for stable
patients) was higher compared to that of currently available metallic
DES [35,36]. The importance of patient selection, lesion preparation,
pre- and post-dilatation and also the consideration of intra-vascular im-
aging have to be underlined [37,38]. A pilot imaging study suggested
suboptimal implantation as an important cause for BVS ST [28]. Use of
intravascular imaging could improve pre-procedural vessel sizing, opti-
mize lesion coverage and eventually reduce adverse events.
Next generation BVS with smaller scaffold struts may reduce the
early event rates in ACS patients. For the current design, usingmore po-
tent P2Y12 inhibitors such as ticagrelor, a direct-acting platelet inhibitor
or cangrelor, an intravenous antiplatelet drug, could be valuable. In
the ATLANTIC trial, ticagrelor was administered prehospital in the
ambulance to STEMI patients, leading to a reduction in ST rate [39].
The CHAMPION PHOENIX trial assessed ischemic complications of PCI
after administration of cangrelor and showed a decrease in these
complications, with no signiﬁcant increase in severe bleeding [40].
The upcoming HORIZONS-ABSORB AMI will compare the perfor-
mance of BVS to DES when cangelor is used on top of heparin or
bivalirudin in STEMI patients [41].Rate of mortality in ACS patients is worse compared with patients
who present with stable CAD [42–45]. In our patient cohort, mortality
was 0% in the ACS population probably reﬂecting our exclusion criteria
for the STEMI population (exclusion of patients presenting with cardio-
genic shock). As shown by our landmark survival analyses, events in the
ACS group are especially clustered in the early phase after BVS implanta-
tion. On the other hand, one-year Kaplan Meier curves for events are
lower in ACS patients. This is probably due to patient selection, where
ACS patients present with different patient and lesion factors (younger
age, less extensive cardiovascular disease andmore often simple lesions),
and the higher intake of prasugrel and ticagrelor in these patients (76.1%
versus 10.4%).
In summary, our results warrant further conﬁrmation in a large-
scale trial with a high number of ACS patients and an optimal im-
plantation strategy tailored at the limitation of this ﬁrst generation
fully bioresorbable scaffolds. Ongoing and upcoming trials such as
the AIDA, Compare Absorb (NCT02486068) and HORIZON-ABSORB
AMI, will provide data derived from larger patient cohorts and in di-
rect comparison to metallic DES [41,46].
5. Limitations
These results are derived from two single-center, single-arm regis-
tries with no direct comparison with metallic DES. The total number
of patients in this study was limited.
Baseline differences in patient and lesion characteristics could have
led to biased outcome in clinical event rates.
Furthermore, deciding which patient or lesion was suitable for
BVS implantation could have led to selection bias. However, there
was a fair amount of patients presenting with ACS and with B2/C
lesions were included, indicating the complexity of the present
study population.
6. Conclusion
Despite the higher rate of early complications due to early ST in the
ACS population, the one-year clinical outcomes for BVS implantations in
ACS patients versus non-ACS patients are comparable. The early ST rate
observed in ACS needs further attention and optimized antiplatelet
therapymay play a role. Angiographic outcomes for BVS in ACS patients
are at least as good as non-ACS patients. Therefore, ACS patients may be
suitable candidates for the treatment with the BVS if early procedural
related complications can be avoided.
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